Assessing Viral Hepatitis Readiness in Vietnam and Philippines

Why It Matters

Achieving hepatitis elimination will reduce liver‑related morbidity, lower health‑system costs, and align Southeast Asia with global disease‑control goals.

Key Takeaways

• Vietnam’s HBV birth‑dose coverage exceeds 95%
• Philippines’ DAA uptake remains under 30% of eligible patients
• Surveillance data gaps hinder accurate disease burden estimates
• Public‑private financing models proposed to fund treatment scale‑up
• Laboratory capacity upgrades critical for rapid diagnosis

Pulse Analysis

Vietnam and the Philippines are at a pivotal juncture in the fight against viral hepatitis, two of the most pressing public‑health challenges in Southeast Asia. While both nations have successfully integrated hepatitis B birth‑dose vaccines into national immunisation schedules—Vietnam reaching near‑universal coverage and the Philippines closing historic gaps—significant disparities remain in hepatitis C management. Direct‑acting antivirals, the cornerstone of cure, are still inaccessible for large segments of the population due to high costs and limited distribution channels. This assessment underscores the urgency of policy reforms that prioritize price negotiations, generic production, and insurance coverage to broaden treatment reach.

Beyond drug access, robust surveillance is essential for tracking progress toward the WHO 2030 elimination targets. The report highlights fragmented data collection, especially in rural provinces where laboratory infrastructure is weak. Investing in point‑of‑care testing, digital health platforms, and regional reference labs can generate real‑time epidemiological insights, enabling targeted interventions. Moreover, integrating hepatitis services with existing HIV and TB programs can leverage established supply chains and community outreach mechanisms, fostering a more efficient health‑system response.

Financing emerges as the linchpin of sustainable hepatitis control. Both countries are exploring blended financing models that combine government budgets, international donor support, and private‑sector investment. By aligning incentives across stakeholders, Vietnam and the Philippines can secure the fiscal space needed for large‑scale DAA procurement, workforce training, and public‑awareness campaigns. Ultimately, a coordinated, well‑funded strategy will not only curb liver disease mortality but also stimulate broader economic benefits through a healthier workforce.